RU2010146701A - Противовирусная терапия - Google Patents
Противовирусная терапия Download PDFInfo
- Publication number
- RU2010146701A RU2010146701A RU2010146701/15A RU2010146701A RU2010146701A RU 2010146701 A RU2010146701 A RU 2010146701A RU 2010146701/15 A RU2010146701/15 A RU 2010146701/15A RU 2010146701 A RU2010146701 A RU 2010146701A RU 2010146701 A RU2010146701 A RU 2010146701A
- Authority
- RU
- Russia
- Prior art keywords
- expression
- sample
- genes
- gene
- patient
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract 11
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract 11
- 238000000034 method Methods 0.000 claims abstract 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract 25
- 230000014509 gene expression Effects 0.000 claims abstract 19
- 239000000523 sample Substances 0.000 claims abstract 15
- 239000013068 control sample Substances 0.000 claims abstract 7
- 208000036142 Viral infection Diseases 0.000 claims abstract 4
- 230000005856 abnormality Effects 0.000 claims abstract 4
- 230000009385 viral infection Effects 0.000 claims abstract 4
- 208000005176 Hepatitis C Diseases 0.000 claims abstract 3
- 108010050904 Interferons Proteins 0.000 claims abstract 3
- 102000014150 Interferons Human genes 0.000 claims abstract 3
- -1 LOC286208 Proteins 0.000 claims abstract 3
- 229940079322 interferon Drugs 0.000 claims abstract 3
- 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 claims abstract 2
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 claims abstract 2
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 claims abstract 2
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 claims abstract 2
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims abstract 2
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 claims abstract 2
- 102100031478 C-type natriuretic peptide Human genes 0.000 claims abstract 2
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 claims abstract 2
- 102100023936 G patch domain-containing protein 11 Human genes 0.000 claims abstract 2
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims abstract 2
- 241000700721 Hepatitis B virus Species 0.000 claims abstract 2
- 102100030690 Histone H2B type 1-C/E/F/G/I Human genes 0.000 claims abstract 2
- 102100030689 Histone H2B type 1-D Human genes 0.000 claims abstract 2
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 claims abstract 2
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 claims abstract 2
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 claims abstract 2
- 101000904738 Homo sapiens G patch domain-containing protein 11 Proteins 0.000 claims abstract 2
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 claims abstract 2
- 101001084682 Homo sapiens Histone H2B type 1-C/E/F/G/I Proteins 0.000 claims abstract 2
- 101001084684 Homo sapiens Histone H2B type 1-D Proteins 0.000 claims abstract 2
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims abstract 2
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 claims abstract 2
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims abstract 2
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims abstract 2
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims abstract 2
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 claims abstract 2
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 claims abstract 2
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 claims abstract 2
- 101000839399 Homo sapiens Oxidoreductase HTATIP2 Proteins 0.000 claims abstract 2
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 claims abstract 2
- 101000952078 Homo sapiens Probable ATP-dependent RNA helicase DDX60 Proteins 0.000 claims abstract 2
- 101001035144 Homo sapiens Probable E3 ubiquitin-protein ligase HERC6 Proteins 0.000 claims abstract 2
- 101000613617 Homo sapiens Protein mono-ADP-ribosyltransferase PARP12 Proteins 0.000 claims abstract 2
- 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 claims abstract 2
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims abstract 2
- 101000580034 Homo sapiens Ras-specific guanine nucleotide-releasing factor RalGPS1 Proteins 0.000 claims abstract 2
- 101000641015 Homo sapiens Sterile alpha motif domain-containing protein 9 Proteins 0.000 claims abstract 2
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims abstract 2
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims abstract 2
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims abstract 2
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims abstract 2
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims abstract 2
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims abstract 2
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 claims abstract 2
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 claims abstract 2
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 claims abstract 2
- 102100027952 Oxidoreductase HTATIP2 Human genes 0.000 claims abstract 2
- 102100034410 Polyribonucleotide nucleotidyltransferase 1, mitochondrial Human genes 0.000 claims abstract 2
- 102100037439 Probable ATP-dependent RNA helicase DDX60 Human genes 0.000 claims abstract 2
- 102100039921 Probable E3 ubiquitin-protein ligase HERC6 Human genes 0.000 claims abstract 2
- 102100040845 Protein mono-ADP-ribosyltransferase PARP12 Human genes 0.000 claims abstract 2
- 102100034930 Protein mono-ADP-ribosyltransferase PARP9 Human genes 0.000 claims abstract 2
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims abstract 2
- 102100027536 Ras-specific guanine nucleotide-releasing factor RalGPS1 Human genes 0.000 claims abstract 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims abstract 2
- 102100034291 Sterile alpha motif domain-containing protein 9 Human genes 0.000 claims abstract 2
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 208000015181 infectious disease Diseases 0.000 claims abstract 2
- 210000004185 liver Anatomy 0.000 claims abstract 2
- 210000005228 liver tissue Anatomy 0.000 claims abstract 2
- 229960000329 ribavirin Drugs 0.000 claims abstract 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims abstract 2
- 230000000638 stimulation Effects 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000009870 specific binding Effects 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 241001440741 CHER virus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Способ определения вероятности того, что пациент, страдающий вирусной инфекцией печени, будет чувствителен к противовирусной терапии, включающей стимуляцию активности интерферона (ИФН), где способ включает: ! (а) анализ образца пациента на экспрессию хотя бы одного гена каждой из нижеследующих групп генов: ! (1) LOC129607, RPLP0 и HERC5, ! (2) HTATIP2 и IFI44L, ! (3) IFI27, IFIT1, G1P2, IRF7, RSAD2, IFI44, OAS3 и IFIT2, ! (4) LAMP3, HERC6, LOC286208, IFIT3, RALGPS1, PARP9, CCDC75 и CNP, ! (5) HIST1H2BG, HIST1H2BD, FLJ20035, PARP12, PNPT1, LGALS3BP, SAMD9 и LOC402560, а также ! (б) сопоставление экспрессии генов в образце с экспрессией тех же генов в контрольном образце. ! 2. Способ по п.1, в котором отклонения в экспрессии генов образце по сравнению с теми же генами в контрольном образце указывает на то, что пациент вероятно не будет чувствителен к упомянутой противовирусной терапии. ! 3. Способ по п.1, в котором отсутствие отклонений в экспрессии генов образце по сравнению с теми же генами в контрольном образце указывает на то, что пациент вероятно будет чувствителен к упомянутой противовирусной терапии. ! 4. Способ по п.1, в котором противовирусная терапия включает пегилированный ИФНα. ! 5. Способ по п.4, в котором противовирусная терапия включает пегИФНα и рибавирин. ! 6. Способ по п.1, в котором вирусная инфекция представляет собой инфекцию вируса гепатита В или вируса гепатита С. ! 7. Способ по п.4, в котором вирус представляет собой вирус гепатита С. ! 8. Способ по п.1, в котором образец включает ткань печени. ! 9. Способ по п.1, в котором анализируют экспрессию пяти, шести, семи, восьми, девяти, 10, 11, 12, 13, 14, 15, 20, 25, 26, 27, 28 или 29 генов по п.1. ! 10. Способ по п.1, в котором экспрессию генов определяют посредством измерения количества генного транс�
Claims (15)
1. Способ определения вероятности того, что пациент, страдающий вирусной инфекцией печени, будет чувствителен к противовирусной терапии, включающей стимуляцию активности интерферона (ИФН), где способ включает:
(а) анализ образца пациента на экспрессию хотя бы одного гена каждой из нижеследующих групп генов:
(1) LOC129607, RPLP0 и HERC5,
(2) HTATIP2 и IFI44L,
(3) IFI27, IFIT1, G1P2, IRF7, RSAD2, IFI44, OAS3 и IFIT2,
(4) LAMP3, HERC6, LOC286208, IFIT3, RALGPS1, PARP9, CCDC75 и CNP,
(5) HIST1H2BG, HIST1H2BD, FLJ20035, PARP12, PNPT1, LGALS3BP, SAMD9 и LOC402560, а также
(б) сопоставление экспрессии генов в образце с экспрессией тех же генов в контрольном образце.
2. Способ по п.1, в котором отклонения в экспрессии генов образце по сравнению с теми же генами в контрольном образце указывает на то, что пациент вероятно не будет чувствителен к упомянутой противовирусной терапии.
3. Способ по п.1, в котором отсутствие отклонений в экспрессии генов образце по сравнению с теми же генами в контрольном образце указывает на то, что пациент вероятно будет чувствителен к упомянутой противовирусной терапии.
4. Способ по п.1, в котором противовирусная терапия включает пегилированный ИФНα.
5. Способ по п.4, в котором противовирусная терапия включает пегИФНα и рибавирин.
6. Способ по п.1, в котором вирусная инфекция представляет собой инфекцию вируса гепатита В или вируса гепатита С.
7. Способ по п.4, в котором вирус представляет собой вирус гепатита С.
8. Способ по п.1, в котором образец включает ткань печени.
9. Способ по п.1, в котором анализируют экспрессию пяти, шести, семи, восьми, девяти, 10, 11, 12, 13, 14, 15, 20, 25, 26, 27, 28 или 29 генов по п.1.
10. Способ по п.1, в котором экспрессию генов определяют посредством измерения количества генного транскрипта мРНК в образце или количества кДНК, производной от упомянутой мРНК.
11. Способ по п.1, в котором экспрессию генов определяют посредством измерения количества кодируемого геном пептида или полипептида в образце.
12. Способ по п.11, в котором количество пептида или полипептида определяют с помощью специфично связывающейся молекулы.
13. Способ по п.1, в котором пациент является человеком.
14. Набор для осуществления способа по любому из пп.1-13, включающий:
(1) средства для анализа образца от пациента на экспрессию хотя бы одного гена из каждой из групп генов, перечисленных в п.1, а также необязательно
(2) средства для сопоставления экспрессии генов в образце с экспрессией тех же генов в контрольном образце.
15. Набор по п.14, включающий одну или несколько специфично связывающихся молекул, которые могут связываться с молекулами, репрезентативными в отношении экспрессии в образце упомянутого гена, где таковая специфично связывающаяся молекула является олигонуклеотидным зондом, антителом или аптамером.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08154878 | 2008-04-21 | ||
| EP08154878.6 | 2008-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010146701A true RU2010146701A (ru) | 2012-05-27 |
Family
ID=39830378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010146701/15A RU2010146701A (ru) | 2008-04-21 | 2009-04-20 | Противовирусная терапия |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110117563A1 (ru) |
| EP (1) | EP2271776A1 (ru) |
| JP (1) | JP2011519551A (ru) |
| KR (1) | KR20110014979A (ru) |
| CN (1) | CN102016072A (ru) |
| AU (1) | AU2009240021B2 (ru) |
| BR (1) | BRPI0910534A2 (ru) |
| CA (1) | CA2719078A1 (ru) |
| IL (1) | IL208351A0 (ru) |
| MA (1) | MA32274B1 (ru) |
| MX (1) | MX2010011587A (ru) |
| NZ (1) | NZ588144A (ru) |
| RU (1) | RU2010146701A (ru) |
| SG (1) | SG190570A1 (ru) |
| WO (1) | WO2009130176A1 (ru) |
| ZA (1) | ZA201006647B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2772921A1 (en) * | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| BR112012011221A2 (pt) * | 2009-11-14 | 2016-04-05 | Hoffmann La Roche | biomarcadores para prever resposta rápida ao tratamento de hcv |
| US9709565B2 (en) | 2010-04-21 | 2017-07-18 | Memed Diagnostics Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
| ES2679107T3 (es) | 2012-02-09 | 2018-08-22 | Memed Diagnostics Ltd. | Distintivos y determinantes para diagnosticar infecciones y métodos para usarlos |
| CN103740755A (zh) * | 2013-12-23 | 2014-04-23 | 中国农业大学 | 猪ifit1基因在抗prrs病毒中的应用 |
| BR112017002884A2 (pt) | 2014-08-14 | 2018-01-30 | Memed Diagnostics Ltd | ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano? |
| US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| CN108699583B (zh) | 2016-03-03 | 2022-11-01 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的rna决定子 |
| US11340223B2 (en) | 2016-07-10 | 2022-05-24 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| CA3027341A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| US11353456B2 (en) | 2016-09-29 | 2022-06-07 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification for appendicitis |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123938A1 (en) * | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US20080161203A1 (en) * | 2006-12-27 | 2008-07-03 | Su Chun-Lin | Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof |
-
2009
- 2009-04-20 AU AU2009240021A patent/AU2009240021B2/en not_active Ceased
- 2009-04-20 MX MX2010011587A patent/MX2010011587A/es not_active Application Discontinuation
- 2009-04-20 US US12/988,760 patent/US20110117563A1/en not_active Abandoned
- 2009-04-20 CA CA2719078A patent/CA2719078A1/en not_active Abandoned
- 2009-04-20 SG SG2013030457A patent/SG190570A1/en unknown
- 2009-04-20 KR KR1020107023467A patent/KR20110014979A/ko not_active Application Discontinuation
- 2009-04-20 CN CN2009801140158A patent/CN102016072A/zh active Pending
- 2009-04-20 RU RU2010146701/15A patent/RU2010146701A/ru not_active Application Discontinuation
- 2009-04-20 JP JP2011505470A patent/JP2011519551A/ja active Pending
- 2009-04-20 NZ NZ588144A patent/NZ588144A/en not_active IP Right Cessation
- 2009-04-20 EP EP09734656A patent/EP2271776A1/en not_active Withdrawn
- 2009-04-20 WO PCT/EP2009/054641 patent/WO2009130176A1/en active Application Filing
- 2009-04-20 BR BRPI0910534A patent/BRPI0910534A2/pt not_active IP Right Cessation
-
2010
- 2010-09-16 ZA ZA2010/06647A patent/ZA201006647B/en unknown
- 2010-09-21 IL IL208351A patent/IL208351A0/en unknown
- 2010-10-15 MA MA33258A patent/MA32274B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2271776A1 (en) | 2011-01-12 |
| MX2010011587A (es) | 2011-05-03 |
| MA32274B1 (fr) | 2011-05-02 |
| SG190570A1 (en) | 2013-06-28 |
| AU2009240021A1 (en) | 2009-10-29 |
| IL208351A0 (en) | 2010-12-30 |
| BRPI0910534A2 (pt) | 2015-09-29 |
| CN102016072A (zh) | 2011-04-13 |
| US20110117563A1 (en) | 2011-05-19 |
| JP2011519551A (ja) | 2011-07-14 |
| NZ588144A (en) | 2012-04-27 |
| ZA201006647B (en) | 2011-05-25 |
| KR20110014979A (ko) | 2011-02-14 |
| WO2009130176A1 (en) | 2009-10-29 |
| CA2719078A1 (en) | 2009-10-29 |
| WO2009130176A9 (en) | 2010-01-07 |
| AU2009240021B2 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010146701A (ru) | Противовирусная терапия | |
| Suppiah et al. | IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study | |
| Danesh et al. | Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation | |
| Jiang et al. | Genetic variation in STAT4 predicts response to interferon‐α therapy for hepatitis B e antigen‐positive chronic hepatitis B | |
| RU2011102818A (ru) | Прогнозирование ответа на противовирусную терапию | |
| Alborzi et al. | Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients | |
| Younossi et al. | Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon‐alfa and ribavirin | |
| Morgan et al. | DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial | |
| Zhang et al. | The gene expression profile of peripheral blood mononuclear cells from EV71-infected rhesus infants and the significance in viral pathogenesis | |
| Huang et al. | Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype | |
| Akkarathamrongsin et al. | High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients | |
| Biswas et al. | Association of TNF-alpha (− 308 A/G) and IFN-gamma (+ 874 A/T) gene polymorphisms in response to spontaneous and treatment induced viral clearance in HCV infected multitransfused thalassemic patients | |
| Sultana et al. | Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C | |
| Khafaei et al. | Impact of IL-6 rs1800795 and IL-17A rs2275913 gene polymorphisms on the COVID-19 prognosis and susceptibility in a sample of Iranian patients | |
| JP2013521497A5 (ru) | ||
| Schaefer et al. | Increased expression of interferon-inducible genes in macaque lung tissues during simian immunodeficiency virus infection | |
| Sivaprasad et al. | The distribution of genotype and allelic frequency of IL28B gene polymorphism in Andhra Pradesh, India | |
| Younossi et al. | Gene expression profile associated with superimposed non‐alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C | |
| Selzner et al. | Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients | |
| Machicote et al. | IL28B SNPs rs12979860 and rs8099917 are associated with inflammatory response in Argentine chronic HCV patients | |
| Xiang et al. | Association of the IFNAR1-17470 and IL-10-592 cytokine variants with susceptibility to chronic hepatitis B viral infections in a Chinese population | |
| Amir et al. | Interleukin 28B gene polymorphisms and chronic Hepatitis C Virus infection | |
| Pedergnana et al. | Refined association of melanoma differentiation‐associated gene 5 variants with spontaneous hepatitis C virus clearance in Egypt | |
| Abdallah et al. | Impact of HCV Genome Structure on Responder to Pegylated Interferon Therapy in Egyptian Patients | |
| Zhang et al. | A lower PBMC estrogen receptor α gene expression in chronic hepatitis B Is Associated with a sustained virological response to pegylated interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130904 |